Form 4: Zai Lab CEO Du Ying Executes Stock Options and Sells Shares Under 10b5-1 Plan

Zai Lab's Chairperson and CEO, Du Ying, exercised stock options and sold American Depositary Shares (ADS) under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Du Ying, Chairperson and CEO of Zai Lab Ltd, executed stock options to acquire American Depositary Shares (ADS).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2024.
• On May 9, 2025, 50,000 stock options were exercised at a price of $0.6, and 46,362 ADSs were sold at a weighted average price of $29.5803, and 3,638 ADSs were sold at a weighted average price of $30.1645.
• On May 12, 2025, 50,000 stock options were exercised at a price of $0.6, and 49,384 ADSs were sold at a weighted average price of $29.4374, and 616 ADSs were sold at a weighted average price of $29.9201.
• Following these transactions, Du Ying directly owns 479,851 ADSs.
• After the transactions, Du Ying holds 292,776 stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information. The market will likely interpret this as a standard part of executive compensation and portfolio management.

Comparison to Industry Standards

• Executive stock option exercises and sales are common in the pharmaceutical industry.
• Companies like BeiGene and Hutchmed also see similar Form 4 filings from their executives.
• The use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact is likely to be minimal as the transactions were pre-planned and executed under a Rule 10b5-1 trading plan.

Key Dates

Keywords

Zai Lab, Du Ying, stock options, ADS, Rule 10b5-1, insider trading, Form 4